Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 12:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 1,096 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Vehicle Clear all
Recruiting Phase 2 Interventional

A Multicenter, Randomized, Vehicle-Controlled, Double-Masked to Open-Label Study to Evaluate the Safety and Efficacy of Lacripep in Subjects With Neurotrophic Keratitis

NCT07568730
View directory record Official record
Conditions
Neurotrophic Keratitis
Interventions
Lacripep, Vehicle Ophthalmic Solution
Drug · Other
Lead sponsor
TearSolutions, Inc.
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
6
States / cities
Tampa, Florida • Carmel, Indiana • Russells Mills, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 18, 2026, 12:23 AM EDT
Completed Phase 3 Interventional Results available

Metvix PDT Versus Vehicle PDT With Aktilite CL128 Lamp in Patients With Actinic Keratosis on the Face and Scalp

NCT00304239
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Metvix-PDT, Vehicle-PDT
Combination Product
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
4
States / cities
Naperville, Illinois • Louisville, Kentucky • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2023 · Synced Oct 18, 2026, 12:23 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability of Hair Stimulating Complex (HSC) in Female Pattern Hair Loss

NCT03662854
View directory record Official record
Conditions
Alopecia
Interventions
Hair Stimulating Complex (HSC), Phosphate Buffered Saline
Biological · Other
Lead sponsor
Histogen
Industry
Eligibility
40 Years to 70 Years · Female only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 21, 2019 · Synced Oct 18, 2026, 12:23 AM EDT
Completed Not applicable Interventional

Reducing Isolation and Feeling of Loneliness During Critical Illness

NCT05537311
View directory record Official record
Conditions
Critical Illness, Social Isolation, Anxiety, Depression, Post Intensive Care Unit Syndrome
Interventions
Social Engagement
Behavioral
Lead sponsor
Kirby Mayer
Other
Eligibility
18 Years to 99 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 14, 2023 · Synced Oct 18, 2026, 12:23 AM EDT
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

Role of NADPH Oxidase in Microvascular Dysfunction Following GDM

NCT05946798
View directory record Official record
Conditions
Gestational Diabetes, Oxidative Stress, Vascular Endothelial Function
Interventions
Acetylcholine, Insulin aspart
Drug
Lead sponsor
Anna Stanhewicz, PhD
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 18, 2026, 12:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability of PNT001 in Healthy Adults

NCT04096287
View directory record Official record
Conditions
Healthy
Interventions
PNT001, Placebo
Biological · Drug
Lead sponsor
Pinteon Therapeutics, Inc
Industry
Eligibility
21 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
4
States / cities
Rogers, Arkansas • San Diego, California • Marlton, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2021 · Synced Oct 18, 2026, 12:23 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Moderate to Severe Acne Vulgaris With Photodynamic Therapy in Adults

NCT05080764
View directory record Official record
Conditions
Acne Vulgaris
Interventions
1h Incubation Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT), 1h Incubation Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient), 3h Incubation Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT), 3h Incubation Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient)
Combination Product
Lead sponsor
Biofrontera Inc.
Industry
Eligibility
16 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
9
States / cities
Fountain Valley, California • San Diego, California • Delray Beach, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 18, 2026, 12:23 AM EDT
Not yet recruiting Phase 2 Interventional

Controlled Study, Performed to Evaluate the Safety and Efficacy of EscharEx and Its Placebo (Gel Vehicle) Compared to Non-surgical Standard of Care in Participants With Venous Leg Ulcers (VLU)

NCT06690177
View directory record Official record
Conditions
Venus Leg Ulcers
Interventions
EscharEx (EX-03), Placebo (Gel vehicle), Non-surgical standard of care (NSSOC)
Drug · Other
Lead sponsor
MediWound Ltd
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
1
States / cities
Maimi, Florida
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 18, 2026, 12:23 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Spinal and Supra-Spinal Pain Mechanisms in Patients With Fibromyalgia

NCT03464292
View directory record Official record
Conditions
Fibromyalgia, Pain
Interventions
Capsaicin Patch 8% or 0.1% Capsaicin Cream, Vehicle Patch
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 14, 2023 · Synced Oct 18, 2026, 12:23 AM EDT
Recruiting Phase 1Phase 2 Interventional

Therapeutic Contact Lens Drug Delivery System (TCL-DDS) in Patients With Recurrent Cystoid Macular Edema

NCT04225611
View directory record Official record
Conditions
Cystoid Macular Edema
Interventions
Dexamethasone
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years to 85 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 26, 2025 · Synced Oct 18, 2026, 12:23 AM EDT
Completed Phase 3 Interventional Results available

Assess the Long Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo

NCT04530344
View directory record Official record
Conditions
Vitiligo
Interventions
ruxolitinib, Vehicle
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
12 Years and older
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
44
States / cities
Hoover, Alabama • Gilbert, Arizona • Fountain Valley, California + 36 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Oct 18, 2026, 12:23 AM EDT
Not yet recruiting Phase 3 Interventional

Phase 3, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Study Assessing the Safety and Efficacy of Urcosimod Ophthalmic Solution in Participants With Neuropathic Corneal Pain (NCP).

NCT07838506
View directory record Official record
Conditions
Neuropathic Corneal Pain
Interventions
Urcosimod ophthalmic solution is a preservative-free topical ophthalmic product; supplied in unit dose ampoules; administered QID for 12-weeks., Vehicle Ophthalmic Solution
Drug · Other
Lead sponsor
Okyo Pharma Ltd
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 18, 2026, 12:23 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Efficacy & Safety of SB206 & Vehicle Gel for the Treatment of MC

NCT03927703
View directory record Official record
Conditions
Molluscum Contagiosum
Interventions
SB206 12%, Placebo
Drug
Lead sponsor
Novan, Inc.
Industry
Eligibility
6 Months and older
Enrollment
355 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
27
States / cities
Scottsdale, Arizona • Hot Springs, Arkansas • Beverly Hills, California + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2023 · Synced Oct 18, 2026, 12:23 AM EDT
Completed Phase 3 Interventional Results available

Bioequivalence Study of Clindamycin Gel 1% in Treatment of Acne Vulgaris

NCT03522441
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Clindamycin 1% Gel, Placebo
Drug
Lead sponsor
Akorn, Inc.
Industry
Eligibility
12 Years to 40 Years
Enrollment
1,125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
10
States / cities
Encino, California • Sherman Oaks, California • Brandon, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2020 · Synced Oct 18, 2026, 12:23 AM EDT
Completed Phase 2 Interventional

Study to Determine the Safety of PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses

NCT00375739
View directory record Official record
Conditions
Actinic Keratosis
Interventions
PEP005
Drug
Lead sponsor
Peplin
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
24
States / cities
Huntsville, Alabama • Tucson, Arizona • Hot Springs, Arkansas + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2016 · Synced Oct 18, 2026, 12:23 AM EDT
Completed Phase 2 Interventional Results available

CP-690-550 Ointment For Chronic Plaque Psoriasis

NCT01246583
View directory record Official record
Conditions
Psoriasis
Interventions
CP-690,550 Ointment 1, Vehicle 1, CP-690,550 Ointment 2, Vehicle 2
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 99 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
8
States / cities
Mobile, Alabama • Los Angeles, California • Orange Park, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2021 · Synced Oct 18, 2026, 12:23 AM EDT
Not listed Phase 2 Interventional

Topical Minocycline Gel for Inflammatory Lesions of Papulopustular Rosacea

NCT03667222
View directory record Official record
Conditions
Papulopustular Rosacea
Interventions
minocycline topical gel, topical gel vehicle
Drug
Lead sponsor
BioPharmX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
12
States / cities
Anaheim Hills, California • Miami, Florida • Miramar, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2019 · Synced Oct 18, 2026, 12:23 AM EDT
Completed Phase 3 Interventional Results available

A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on AK on Face or Scalp

NCT03285477
View directory record Official record
Conditions
Actinic Keratoses
Interventions
Placebo, KX2-391 Ointment 1%
Drug
Lead sponsor
Almirall, S.A.
Industry
Eligibility
18 Years and older
Enrollment
351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
30
States / cities
Mobile, Alabama • Glendale, Arizona • Fremont, California + 27 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2021 · Synced Oct 18, 2026, 12:23 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of Trans Sodium Crocetinate (TSC) for Treatment of Suspected Stroke

NCT03763929
View directory record Official record
Conditions
Stroke, Acute
Interventions
Trans-Sodium Crocetinate, Placebo
Drug · Other
Lead sponsor
Diffusion Pharmaceuticals Inc
Industry
Eligibility
40 Years to 85 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Los Angeles, California • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 18, 2021 · Synced Oct 18, 2026, 12:23 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Topical Administration of FMX101 in the Treatment of Moderate-to-Severe Acne Vulgaris

NCT03271021
View directory record Official record
Conditions
Acne Vulgaris
Interventions
FMX101, Vehicle Foam
Drug
Lead sponsor
Vyne Therapeutics Inc.
Industry
Eligibility
9 Years and older
Enrollment
1,488 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
98
States / cities
Phoenix, Arizona • Tucson, Arizona • Bryant, Arkansas + 83 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2022 · Synced Oct 18, 2026, 12:23 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Evaluation of EB01 Cream for the Treatment of Chronic Allergic Contact Dermatitis

NCT03680131
View directory record Official record
Conditions
Allergic Contact Dermatitis
Interventions
EB01 Cream Placebo, EB01 Cream 0.2%, EB01 Cream 1.0%, EB01 Cream 2.0%
Drug
Lead sponsor
Edesa Biotech Inc.
Industry
Eligibility
18 Years and older
Enrollment
211 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
14
States / cities
Long Beach, California • Washington D.C., District of Columbia • Delray Beach, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2024 · Synced Oct 18, 2026, 12:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Skin Irritation Potential of PBI-100 Topical Cream in Healthy Participants

NCT04882631
View directory record Official record
Conditions
Healthy Volunteers
Interventions
PBI-100 Topical Cream, Positive Control - Sodium laurel sulfate (SLS), PBI-100 Topical Cream, Vehicle, Negative Control
Drug · Other
Lead sponsor
Pyramid Biosciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Newtown Square, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 27, 2022 · Synced Oct 18, 2026, 12:23 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines

NCT00888914
View directory record Official record
Conditions
Lateral Canthal Lines, Crow's Feet, Facial Wrinkles
Interventions
RT001, Vehicle Comparator
Drug · Other
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
30 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
4
States / cities
San Francisco, California • New York, New York • White Plains, New York
Source: ClinicalTrials.gov public record
Updated Nov 19, 2013 · Synced Oct 18, 2026, 12:23 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Nerinetide in Participants With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy Excluding Thrombolysis

NCT04462536
View directory record Official record
Conditions
Stroke, Acute
Interventions
Placebo, Nerinetide
Drug
Lead sponsor
NoNO Inc.
Industry
Eligibility
18 Years and older
Enrollment
850 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
17
States / cities
Phoenix, Arizona • Torrance, California • Englewood, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2025 · Synced Oct 18, 2026, 12:23 AM EDT